MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramPiyanping Anti-Itch Lotion: Recall - Incorrect Active IngredientAUDIENCE: Consumer, Pharmacy ISSUE: Lucky Mart Inc. is voluntarily recalling lots C14005, C16001 and C16002 of Piyanping Anti-Itch Lotion to the consumer level. The product was manufactured using the active pharmaceutical ingredient dexamethasone rather than hydrocortisone. Dexamethasone is not listed as an ingredient in the labeling. Dexamethasone is a higher potency steroid than hydrocortisone and may have a longer half-life; it could potentially cause serious side effects in patients applying the cream multiple times daily. There is a reasonable probability of any or all of the following side effects of topical steroids which include but are not limited to skin changes (whitening, thinning), adrenal suppression (high blood sugar, weakened immunity, electrolyte imbalances, emotional lability, slowing of growth in children), glaucoma, and cataracts. To date Lucky Mart Inc. has not received any reports of adverse events related to this recall. BACKGROUND: The product is an itch lotion and is indicated for the temporary relief of itching associated with minor skin irritations, inflammation, and rashes in adults and children ages two and older. Products are packaged in a 0.67 oz (20g) tube in a paper carton. Lots C14005 (Exp. 03/2017), C16001 (Exp. 12/2018), C16002 (Exp. 12/2018). NDC 68085-8012-4. Piyanping Anti-Itch Lotion was distributed Nationwide in the USA to herbal and ethnic grocery stores. Lot # and Expiration Date can be found on the right side of the box, opposite of the barcode. RECOMMENDATION: Consumers that may have product which is being recalled should stop use and return to place of purchase. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this product and are encouraged to report any adverse events to FDA’s MedWatch Adverse Event Reporting Program:
Read the MedWatch safety alert, including a link to the press release, at: You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your email address to log in. If you have questions or problems with the subscription service, please visit subscriberhelp.govdelivery.com. This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).
|
